By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arete Therapeutics 

3912 Trust Way

Hayward  California  94545  U.S.A.
Phone: 510-785-7060 Fax: 510-785-7061



Company News
Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 6/9/2009 9:21:34 AM
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes Phase II Study in Patients with Impaired Glucose Tolerance Designed to Confirm Therapeutic Activity 2/10/2009 10:32:27 AM
Arete Therapeutics Reports Positive Phase I Data for AR9281 12/22/2008 9:55:24 AM
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 11/19/2008 6:14:07 AM
Arete Therapeutics Bolsters Management Team Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery 10/30/2008 8:26:14 AM
Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer 7/8/2008 8:34:44 AM
Arete Therapeutics Adds Jim Bristol as Scientific and Strategic Advisor 1/22/2008 8:07:25 AM
Arete Therapeutics Appoints Donald Santel to Board of Directors 12/6/2007 11:42:01 AM
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 11/1/2007 7:22:35 AM
Arete Therapeutics (Jobs) Raises $35 Million Series A 5/23/2007 10:17:05 AM